Patent intelligence · US
US 9820964
Ultrapure tetrahydrocannabinol-11-oic acids
Ultrapure tetrahydrocannabinol-11-oic acids
Patent details — US 9820964
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 21, 2017
- Expiration
- Nov 16, 2037
- Applicant
- Corbus Pharmaceuticals, Inc.
- Claims
- 21
- CPC classes
- A61K, A61K31/352, A61K9/0014, A61K9/0019
Quick answer
US 9820964 (Ultrapure tetrahydrocannabinol-11-oic acids) is held by Corbus Pharmaceuticals, Inc.. Status: granted. Granted Nov 21, 2017. Expires Nov 16, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Corbus Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K31/352, A61K9/0014, A61K9/0019, A61K9/0048, A61K9/0053
More from Corbus Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11052066
Ultrapure tetrahydrocannabinol-11-oic acids
granted -
US 10369131
Ultrapure tetrahydrocannabinol-11-oic acids
granted -
US 10154986
Ultrapure tetrahydrocannabinol-11-oic acids
granted -
US 10085964
Ultrapure tetrahydrocannabinol-11-oic acids
granted -
US 9801849
Ultrapure tetrahydrocannabinol-11-oic acids
granted
Frequently asked questions
What is US patent 9820964?
US 9820964 (Ultrapure tetrahydrocannabinol-11-oic acids) is held by Corbus Pharmaceuticals, Inc.. Status: granted. Granted Nov 21, 2017. Expires Nov 16, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9820964?
Corbus Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 9820964 expire?
Our index shows an expiration date of Nov 16, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.